Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 14-week, double-blind Phase II trial in 371 patients, Topamax reduced the percentage of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury